Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Another disappointment raises fresh doubts about CytomX’s extensively partnered masked therapeutics.
The Echelon-3 study seemed doomed, but it just read out positively for overall survival.
Tamarack data are a 2024 catalyst, so why has MacroGenics brought forward a follow-on molecule?
New clinical trial entrants include the group’s attempt at targeting Sting, a field that has seen many setbacks.
BeiGene has a strong presence at this year’s AACR, which features several notable duels.
Projects from the likes of BioNTech, Transgene and Scancell will feature, but still have much to prove.